

Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes

1 Alfredo Ramírez-Reveco¹; Gerardo Velázquez^{1,3} Christopher Aros^{1,8}; Gabriela Navarrete^{1,8};
2 Franz Villarroel-Espindola², Maritza Navarrete³, Alberto Fica⁴, Anita Plaza⁵, Natalia Castro⁵,
3 Claudio Verdugo^{5,6}, Gerardo Acosta-Jamett^{5,7} and Cristóbal Verdugo^{5,7*}

4

5 ¹Instituto de Ciencia Animal, Facultad de Ciencias Veterinarias, Universidad Austral de
6 Chile, Valdivia, Chile.

7 ²Laboratorio Medicina Traslacional, Instituto Oncológico Fundación Arturo López Pérez,
8 Santiago, Chile.

9 ³Laboratorio de Biología Molecular, Hospital Base de Valdivia (HBV), Valdivia, Chile.

10 ⁴SubDepartamento de Medicina, Hospital Base Valdivia; Instituto Medicina, Facultad de
11 Medicina, Universidad Austral de Chile, Valdivia, Chile

12 ⁵Center for the Surveillance and Evolution of Infectious Diseases (CSEID), Universidad
13 Austral de Chile, Valdivia, Chile

14 ⁶Instituto de Patología Animal, Facultad de Ciencias Veterinarias, Universidad Austral de
15 Chile, Valdivia, Chile.

16 ⁷Instituto de Medicina Preventiva, Facultad de Ciencias Veterinarias, Universidad Austral de
17 Chile, Valdivia, Chile.

18 ⁸Escuela de Bioquímica, Facultad de Ciencias, Universidad Austral de Chile, Valdivia Chile.

19

20 *Correspondence:

21 Dr. Cristobal Verdugo

22 cristobal.verdugo@uach.cl

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24 Grant ANID COVID N°0585.

25 **Key words:** SARS-CoV-2, COVID19, Immunoglobulins, Np and RBD, ELISA

26

27 **ABSTRACT**

28 The main objective of this study was to estimate the performance, under local
29 epidemiological conditions, of two in-house ELISA assays for the combined detection of
30 anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulins. A total of 94 serum samples were
31 used for the assessment, where 44 corresponded to sera collected before the pandemic (free
32 SARS-CoV-2 antibodies), and 50 sera were collected from confirmed COVID-19 patients
33 admitted to the main public hospital in the city of Valdivia, southern Chile. The Np and RBD
34 proteins were separately used as antigens (Np and RBD ELISA, respectively) to assess their
35 diagnostic performance. A receiver operating characteristic (ROC) analysis was performed to
36 estimate the optical density (OD) cut-off that maximized the sensitivity (Se) and specificity
37 (Sp) of the ELISA assays. Np ELISA had a mean Se of 94% (95% CI = 83.5 – 98.8%) and a
38 mean Sp of 100% (95% CI = 92.0 – 100%), with an OD 450 nm positive cut-off value of
39 0.88. On the other hand, RBD ELISA presented a mean Se of 96% (95% CI = 86.3 – 99.5%)
40 and a mean Sp of 90% (95% CI = 78.3 – 97.5%), with an OD 450 nm positive cut off value
41 of 0.996. Non-significant differences were observed between the Se distributions of Np and
42 RBD ELISAs, but the latter presented a significant lower Sp than Np ELISA. In parallel,
43 collected sera were also analyzed using a commercial lateral flow chromatographic
44 immunoassay (LFCI), to compare the performance of the in-house ELISA assays against a
45 commercial test. The LFCI had a mean sensitivity of 94% (95% CI = 87.4 – 100%) and a
46 mean specificity of 100% (95% CI = 100 – 100%). When compared to Np ELISA, non-
47 significant differences were observed on the performance distributions. Conversely, RBD

48 ELISA had a significant lower Sp than the LFCI. Although, Np ELISA presented a similar
49 performance than the commercial test, this was 2.5 times cheaper than the LFCI assay. Thus,
50 the in-house Np ELISA could be a suitable alternative tool, in resource limited environments,
51 for the surveillance of SARS-CoV-2 infection, supporting further epidemiological studies.

52

53 **INTRODUCTION**

54 The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
55 etiological agent of COVID-19, has caused a global pandemic, which 2.5 years after the first
56 reported case (December 2019) has been linked to more than 5 million deaths and more than
57 two hundred million cumulative cases [1]. Since its emergence, several serological assays
58 have been developed to detect the presence of specific antibodies against SARS-CoV-2 [2].
59 Although, serological approaches cannot distinguish between acute and chronic infection,
60 these types of tests are useful for *i*) the identification of individuals who have developed an
61 immune response, *ii*) aid in contact tracing, *iii*) monitoring infection dynamic in the general
62 population, and *iv*) the development of clinical trials [3,4].

63 The immunoglobulin time response is between 4 to 10-14 days after the onset of symptoms,
64 which limits its applicability for the diagnosis during the acute phase [5,6]. However, the IgM
65 and IgA anti SARS-CoV-2 antibodies develop rapidly in response to the infection, and their
66 detection can significantly increase the diagnostic sensitivity of SARS-CoV-2 infection,
67 when serological tests are combined with molecular tests [7]. In particular, IgA antibodies
68 play an important role in mucosal immunity, where IgA may be a better marker of early
69 infection than IgM [8–10]. However, most COVID-19 serological tests are based on the
70 detection of IgM and/or IgG antibodies [11]. The preference of IgG and/or IgM detection
71 over IgA, probably is related to a lower specificity of this immunoglobulin despite an earlier
72 onset in comparison with IgG and IgM [9]. Nevertheless, the use of assays detecting IgA,

73 along with IgG and IgM, may be useful in scenarios where it is necessary to maximize the
74 diagnostic sensitivity of the test, such as a screening tool for a surveillance program, for
75 example. Additionally, IgA assays may also be helpful in patients with atypical symptoms, in
76 asymptomatic cases, or when RT-qPCR results remains negative in suspected subjects
77 [12,13].

78 The detection of circulating antibodies against SARS-CoV-2, as part of a surveillance
79 program, requires the use of tools with known sensitivity and specificity [14]. Those
80 parameters would allow to estimate key epidemiological variables, such as the true
81 prevalence (TP), when the assay is used in randomized studies. Moreover, accurate TP
82 estimates could be used to assess the performance of passive surveillance systems that most
83 countries have implemented as part of their COVID-19 control strategies [15,16].

84 The main serologic assays used for SARS-CoV-2 detection include the lateral flow
85 chromatographic immunoassay (LFCA) and ELISA tests. In these kinds of assays, the most
86 used viral proteins as antigens are the nucleocapsid protein (Np), which plays a role in the
87 transcription and replication of the virus [17,18] and the subunits S1 and S2 of the spike (S)
88 protein [19]. Specifically, S1, containing the receptor binding domain (RBD) for the host
89 angiotensin-converting enzyme (ACE2) receptor; and the S2, containing elements needed for
90 membrane fusion [20,21]. Previous evidence has suggested that the IgG antibodies aiming for
91 the S protein are more specific than the anti-Np protein [22,23]. On the other hand, the IgG
92 aiming Np may be more sensitive than those anti-S proteins, particularly in the early phase of
93 infection [22,23]. This could be explained by the relatively high homology in aminoacidic
94 sequence of the SARS-CoV-2 protein Np with the nucleocapsid proteins of other
95 Coronaviridae and other viruses [22,24]. Thus, the increased sensitivity of the anti-Np
96 antibody response detection could be at the expense of specificity. The latter may be due to
97 the potential cross-reaction of serological tests to other similar viruses circulating in the target

98 population, increasing the false positive rate. In consequence, the performance of any
99 serological assay, such as ELISA tests must be optimized and validated under local
100 conditions, accounting for endemically circulating viruses.

101 The objective of this study was to evaluate and validate two in-house ELISA assays for the
102 combined detection of SARS-CoV-2 IgG, IgM and IgA antibodies. To be used for the
103 surveillance of COVID-19 in the general population, and to support further epidemiological
104 studies. In particular, diagnostic performance indices, such as sensitivity (Se) and specificity
105 (Sp), were estimated using sera from pre-pandemic individuals and confirmed COVID-19
106 patients

107

108 **MATERIAL AND METHODS**

109 **Study population, sample collection and ethics approvals**

110 The present study was developed following the Standards for the Reporting of Diagnostic
111 Accuracy Studies (STARD) guidelines proposed by Cohen et al. [25]. A total of 94
112 individuals were enrolled, where 50 corresponded to confirmed cases of SARS-CoV-2
113 infection (24 women and 26 men), and 44 corresponded to sera collected between June and
114 July 2019, thus regarded as free of SARS-CoV-2 antibodies sera (pre-pandemic samples). All
115 50 confirmed cases corresponded to unvaccinated patients admitted to the Hospital Base de
116 Valdivia (HBV), Valdivia, southern Chile, from April to November 2020, and they were
117 confirmed by a standard RT-qPCR assay using nasopharyngeal swab samples, as previously
118 described [26]. At the time of sera collection at the HBV, all were symptomatic cases,
119 presenting different degrees of COVID-19 complications, from very mild to severe, which
120 eventually required hospitalization at the HBV. In this line, confirmed cases presented a
121 median of 4 days (interquartile range (IQR): 2 – 6 days) between symptoms onset and RT-
122 qPCR diagnosis, whereas serum samples were collected with a median of 11.5 days (IQR: 9 –

123 15 days) after symptoms onset. This group presented a median age of 58 years (1st Q: 52.5
124 years and 3rd Q: 68.5 years). On the other hand, samples from non-COVID-19 individuals
125 were obtained from a serum bank of an epidemiological study on cystic echinococcosis,
126 where sera were collected from the general population in the Coquimbo region, Chile. This
127 group was composed of 27 women and 17 men, with a median age of 53.5 years (1st Q: 41.5
128 years and 3rd Q: 63.5 years), and 7 out of 44 control-participants presented some type of
129 chronic disease, mainly diabetes.

130 Serum samples from non-COVID-19 individuals were obtained and handled following the
131 protocol accepted by the Scientific Ethics Committee of the Faculty of Medicine at the
132 Universidad Católica del Norte, Coquimbo-Chile, approved under the resolution
133 CECFAMED-UCN N ° 81/2019. In short, 5 cc of blood was obtained by peripheral
134 venipuncture from volunteers who attended an ultrasound survey for detecting cystic
135 echinococcosis in urban and rural areas in northern Chile. Blood samples were then
136 centrifuged on the same day using a portable centrifuge (Mobilspine, Vulcon Technologies,
137 Richmond, USA), serum was separated and kept in liquid nitrogen in the field and then
138 transferred to a -80°C freezer until further analysis. The samples from the confirmed COVID-
139 19 patients were collected following the sample collection protocol of the HBV, where 6 cc
140 of blood were obtained by peripheral venipuncture using yellow or red cap tubes and
141 processed before 4 hours. The use of stored sera, for COVID-19 research purposes, was
142 authorized by the Scientific Ethics Committee of the Servicio de Salud Valdivia (SSV),
143 Ministry of Health of Chile, under the resolution SSV Ord.N°187/2020.

144

145 **Study design and laboratory analyzes**

146 The in-house ELISA aims for the combined detection of specific anti-SARS-CoV-2 isotype
147 antibodies (IgA, IgM, and IgG) for the surveillance of COVID-19. To assess the performance

148 of this assay, sera from pre-pandemic and confirmed cases were assessed by the in-house
149 ELISA test using Np and RBD proteins separately as antigens (Np ELISA and RBD ELISA,
150 respectively), in order to evaluate the performance of each protein. Additionally, analyzes
151 were run in in duplicate and reported optical density (OD) corresponded to the mean between
152 runs. As a quality assurance element, the coefficient of variation between runs was estimated.
153

154 **In-house ELISAs for combined detection of specific SARS-CoV-2 antibodies**

155 Proteins: Recombinant SARS-CoV-2 Np protein (Met1-Ala419, with a C-terminal 6-His tag)
156 from Spodoptera frugiperda (R&D System, Catalog Number 10474.CV) (accession #
157 YP_009724397.2). Recombinant SARS-CoV-2 S1 subunit protein (Arg319-Phe541, with a
158 C-terminal 6-His tag) of Host Cell Receptor Binding Domain (RBD) from HEK293 cells
159 (Raybiotech, Catalog Number: 230-30162) (accession # QHD43416.1); Coating step: A final
160 volume of 50 µl of 20 ng Np or RBD proteins [27] were seeded in a 96-well plate in
161 carbonate buffer pH 9.6 per well and incubated overnight at 4°C. Washing step: After the
162 incubation time, 3 washes of 5 minutes were carried out with PBS 1x-Tween20 0.05%.
163 Blocking step: the wells were blocked with 200 µl of blocking solution (1x PBS, 5% BSA,
164 0.05% Tween20) for 2 hours at 37° C, and the content of the plate was discarded, and the
165 washing phase was carried out as previously described. Loading of serum samples: A final
166 volume of 50 microliters of sample (1:40 dilution in PBS buffer 0.1% w/v of BSA; 0.05% v/v
167 Tween20) [27,28] was loaded and incubated for 2 hours at 37° C. Washing step: After the
168 incubation time, 3 washes of 5 minutes were carried out with PBS 1x-Tween20 0.05%.
169 Antibodies hybridization step: 100 µl per well of Anti-Human IgA/IgG/IgM (H&L) goat
170 polyclonal antibody (HRP) (Rockland, R.609-103-130) at a dilution of 1: 10,000 in PBS
171 buffer 0.1% BSA-0.05% Tween20, were added and incubated for 1 hour at 37° C, the content
172 of the plate was discarded, and the washing phase was carried out as previously described.

173 Finally, the washed wells were developed with TMB reaction and read at 450 nm using a
174 microplate reader HR801 (Shenzhen Highcreation Technology Co. Ltd).

175

176 **Performance comparison between the in-house ELISAs and a commercial test**

177 To compare the performance of the in-house assays (Np & RBD ELISAs) against a
178 commercially available test. The collected sera were additionally tested using a LFCI kit (The
179 Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow),
180 LIVZON, China). This LFCI test was widely used by the Chilean Health Services in the early
181 stages of the pandemic, and it can separately detect IgG and IgM immunoglobulin isotypes,
182 using Np as antigen. For this assessment, the LFCI interpretation criteria considered that any
183 serum showing a signal for IgG or IgM was positive to SARS-CoV-2 infection. Statistical
184 comparison between the LFCI and in-house assays are described below. To complement the
185 comparison between the in-house ELISAs and the commercial LFCI test performance, a cost
186 per sample analyzed at laboratory level was included. The latter evaluation only considered
187 the cost of the reagents (in-house ELISAs) or the commercial value of the kit (LFCI).

188

189 **Statistical analysis**

190 Collected data were analyzed using GraphPad Prism 6 statistical software (USA) and the R
191 software v4.0.2 [29]. They included mean values and standard deviation (mean \pm SD) of the
192 optical density (OD) distribution. Those values were subjected to a background subtraction
193 step before data analysis. For comparative analysis of the infected and pre-pandemic OD
194 distributions, a Mann-Whitney U-test was used. A receiver operating characteristic (ROC)
195 analysis was conducted to determine the best OD cut-off for the in-house ELISA tests, where
196 sample size was calculated using the equation proposed by Obuchowski, N [30], estimating a
197 minimum of 43 infected and 43 uninfected to yield a study power of 80%, a significance

198 level of 5%, and an expected area under the curve (AUC) of 65%. The ROC and AUC values,
199 in addition to the sensitivity and specificity values, for Np or RBD antigens, were calculated
200 by comparing infected (sera from confirmed COVID-19 patients) and non-infected specimens
201 (sera from pre-pandemic individuals), based on a logistic regression model. The agreement
202 between Np ELISA and RBD ELISA results were assessed using the Cohen' kappa index and
203 the paired McNemar's test. Statistical differences in sensitivity and specificity distributions
204 between Np and RBD ELISAs were evaluated using the Kolmogorov–Smirnov test. The
205 overlap area between Np and RBD sensitivity and specificity curves was estimated using the
206 “overlapping” package [31] for the R software. Finally, in-house ELISAs and LFCI results
207 were cross tabulated in two-by-two tables and the agreement between them was also
208 evaluated using Cohen' kappa index and the paired McNemar's test, in addition to the
209 Kolmogorov–Smirnov test to assess statistical differences between the performance
210 distributions of both tests, where Np ELISA and RBD ELISA were separately compared
211 against the commercial LFCI test.

212

213 **RESULTS**

214 **In-house ELISAs for specific SARS-CoV-2 antibodies using Np or RBD antigens**

215 The Figure 1 shows a representative scheme of used proteins and their location in the SARS-
216 CoV-2 virus, together with the OD distributions of the Np ELISA (left) and RBD ELISA
217 (right) for confirmed cases and controls. At the comparison between duplicated runs, both
218 assays showed an adequate consistency, and a low error level, with intra-assay variation of
219 11.2% and 13.4% for Np and RBD ELISAs, respectively. In this way, antibodies against Np
220 protein showed that sera from COVID-19 patients had a significantly higher (97%)
221 absorbance than sera from pre-pandemic individuals (1.02+/-0.12 vs 0.51+/-0,13 OD,
222 respectively) ($P < 0.0001$). On the other hand, although to a lesser extent, the immunoassay

223 against the RBD protein also showed that sera from patients with COVID-19 presented a
224 significantly higher absorbance (43.5%) than sera from pre-pandemic individuals (1.09 +/-
225 0.03 vs 0.71 +/- 0.18 OD, respectively) ($P < 0.0001$). Interestingly, sera from confirmed
226 COVID-19 patients showed a more homogeneous distributions in their absorbances with the
227 RBD immunoassay than with Np (Figure 1, right and left, respectively). Furthermore, these
228 distributions suggest that most of the analyzed sera presented antibodies that recognize and
229 bound to both proteins (Np and RBD), and only 2 patients presented antibodies just against
230 the RBD protein.

231

232 **In-house ELISAs performance assessment (sensitivity and specificity estimation)**

233 The ROC analysis of the Np ELISA indicated a mean sensitivity of 94% (95% CI = 83.5 –
234 98.8%) and a mean specificity of 100% (95% CI = 92.0 – 100%), with AUC of 0.99 (95%
235 CI: 0.97 – 1.00) and an OD 450 nm positive cut-off value of 0.88 (Figure 2A). On the other
236 hand, the ROC analysis of the RBD ELISA had a mean sensitivity of 96% (95% CI = 86.3 –
237 99.5%) and a mean specificity of 90% (95% CI = 78.3 – 97.5%), with AUC of 0.96 (95% CI:
238 0.91-1.00) and an OD 450 nm positive cut off value of 0.996 (Figure 3B). Those cut-offs
239 represent the point in the ROC curves where the sensitivity and specificity were maximized
240 for this set of samples.

241 The agreement between Np and RBD ELISAs was assessed as substantial to perfect
242 ($\kappa=0.81$, 95% CI = 0.69 – 0.93) based on the qualitative scale interpretation proposed by
243 Landis and Koch [32] of Cohen's kappa values. Additionally, the dichotomous ELISA results
244 (positive/negative) were not statistically different ($P = 0.18$) between the two antigens.
245 Although RBD ELISA presented a relatively higher sensitivity than Np ELISA, those
246 differences were not statistically significant ($P = 0.37$), with an overlapping area between
247 both curves of 69.7% (Figure 3A). Conversely, the use of RBD protein as antigen was

248 associated to a statistically lower ($P < 0.01$) specificity, with a shared distribution of 10.8%
249 between the Np and RBD proteins (Figure 3B).

250

251 **In-house ELISAs and commercial LFCI test comparison**

252 The cross-tabulation between the LFCI test results and SARS-CoV-2 infection status are
253 presented in Table 1, whereas the cross-tabulation of the dichotomous ELISA and
254 commercial test results are shown in Table 2. Based on the infection status (gold standard),
255 the LFCI test presented a mean sensitivity of 94% (95% CI = 87.4 – 100%) and a mean
256 specificity of 100% (95% CI = 100 – 100%). The Cohen' kappa index showed a substantial
257 to perfect (kappa=0.89, 95% CI = 0.80 – 0.98) agreement between the Np ELISA and the
258 LFCI test, whereas the agreement between RBD ELISA and the LFCI test was categorized as
259 substantial kappa=0.78, 95% CI = 0.66 – 0.91). Non-significant differences in the sensitivity
260 ($P = 0.999$) or specificity ($P = 0.999$) distributions were observed for the comparison between
261 Np ELISA and the LFCI test. Conversely, the comparison between RBD ELISA and the
262 LFCI test render a significant difference in the specificity distribution ($P < 0.01$), but non-
263 differences were observed between them for the sensitivity distributions ($P = 0.999$). The use
264 of the LFCI had a cost of \$10.57 USD per serum analyzed, whereas the Np ELISA and RBD
265 ELISA had costs of \$4.23 USD and \$2.65 USD per serum, respectively. Thus, the in-house
266 ELISAs were between 2.5 – 4.0 times cheaper than the used commercial test.

267

268 **DISCUSSION**

269 The present research reports the performance estimation of two in-house ELISA assays for
270 the surveillance of SARS-CoV-2 infection, which showed a comparable performance than a
271 commercial test but at a fraction of the cost. Thus, they may be alternative tools for
272 conducting large epidemiological studies in resource limited environments, such as

273 developing countries. However, the in-house ELISAs require more qualified personnel than
274 the commercial kit, in addition to be more time consuming. In the present study, labor was
275 not considered in the cost comparison. Despite the latter, it is important to note that full-time
276 technicians are commonly present at university laboratories, where a more frequent problem,
277 in developing countries, is the lack of resources to buy reagents rather than labor availability.
278 The OD cut-off optimization and performance estimates considered local epidemiological
279 conditions; thus, study results represent the expected performance of the assays in the target
280 population. ROC analysis indicated a non-significant higher sensitivity and statistically
281 significant lower specificity of immunoglobins targeting RBD in comparison to Np. In
282 opposition, previous studies have shown a higher Np sensitivity than RBD, and higher
283 specificity of RBD than Np [22,23]. Even though these authors argue that this phenomenon
284 occurs in the early phase of infection, with IgG as the main isotype. In this line, Burbelo et al.
285 [17] showed in a longitudinal study that antibodies against Np emerged before antibodies
286 against the S protein. In the present study, confirmed COVID-19 cases had manifested
287 clinical signs before serum collection (median = 11.5 days, IQR: 9 – 15 days). Thus,
288 sensitivity and specificity results reflect the performance of Np and RBD antigens at later
289 stages of the infection under local conditions. Moreover, considering that the intended use of
290 the in-house ELISA assays is for surveillance purposes, study outputs could represent the
291 expected performance in the general population, for the detection of past infections of SARS-
292 CoV-2. A recent meta-analysis study [19], assessing the performance of serological tests for
293 the detection of antibodies against SARS-CoV-2, has shown that ELISA tests (detecting IgG
294 or IgM) present lower sensitivity than the assays evaluated in this study, where on average
295 those assays presented a sensitivity of 84.3% (95% CI: 75.6 – 90.9%). On the other hand, that
296 meta-analysis showed a comparable specificity (range 96.6 – 99.7%), at least for Np ELISA.
297 In this sense, the combined capture of three immunoglobulins, and particularly the inclusion

298 of IgA, could contribute to explaining the higher sensitivity observed. Similarly, Ma et al.
299 [28] reported that measuring IgA in addition to IgG or IgM would increase the sensitivity of
300 the assay. In this line, previous reports have indicated that SARS-CoV-2 elicits robust
301 humoral immune responses, including the production of IgM, IgG, and IgA immunoglobulin
302 isotypes [33]. Patients have been shown to achieve seroconversion and produce detectable
303 antibodies within 20 days from the symptom onset, though the kinetics of IgM and IgG
304 production was variable [4,34,35]. A serological screening that includes the detection of IgA,
305 IgM and IgG could be more consistent as a strategy to prevent the spread of the virus, given
306 the need to maximize the sensitivity [13], when the diagnostic assay is used as a screening
307 test.

308 Based on the results of the Np and RBD in-house ELISAs, the combined detection of three
309 immunoglobulin isotypes (IgA, IgM and IgG) could be more sensitive than assays that only
310 detect one or two immunoglobulin isotypes, particularly for screening purposes or in studies
311 to evaluate the exposition levels in the general population to SARS-CoV-2 virus, regardless
312 of stage, severity, and symptoms of COVID-19 disease. However, the increase in sensitivity
313 is offset by the reduction in specificity, which was especially evident when the RBD antigen
314 was used. This could be also appreciated when contrasting OD distributions for both antigens
315 (Figure 2), where the comparison between control sera showed that RBD ELISA tend to have
316 higher OD values than Np ELISA in this group, indicating a lower specificity of this antigen.

317

318 **CONCLUSIONS**

319 Considering the intended purpose of the in-house ELISA, a relevant element was to obtain
320 accurate sensitivity and specificity estimates, to support further epidemiological studies. In
321 this sense, estimates for Np ELISA presented a variation (in relation to the mean) between 8
322 – 16%, whereas RBD ELISA presented a variation between 14 – 21%. Thus, relatively

323 precise estimates were obtained. Moreover, at the comparison with the commercial LFCI test,
324 the Np ELISA presented a comparable performance than the LFCI test, while the RBD
325 ELISA presented a significant lower specificity than the LFCI test and the Np ELISA.
326 Therefore, it can be concluded that the Np ELISA is a better assay than RBD ELISA, which
327 presented performance comparable to a commonly used commercial test, but at a quarter of
328 the cost, making it a viable alternative for surveillance studies in developing countries.

329

330 **DECLARATIONS**

331 **Competing interest:** The authors declare that the research was conducted in the absence of
332 any commercial or financial relationships that could be construed as a potential conflict of
333 interest.

334

335 **Author Contributions:** CV (Cristobal) and ARR conceived the idea; CV (Cristobal), ARR,
336 AF, MN, FVE, NC, and AP designed sampling collections and experimental procedures. GV,
337 CA, GN performed laboratory analysis. CV (Cristobal), GA, and CV (Claudio) made the
338 statistical analysis. All the authors wrote, discussed, and approved the final version of this
339 manuscript.

340

341 **Funding:** This work received financial support from the National Agency for Research and
342 Development (ANID) of the Ministry of Sciences of Chile, grant number: ANID COVID
343 N°0585.

344

345 **Acknowledgements:**

346 A special thanks to Dr. Ratto (Animal Science Institute, UACH) for the facilities granted for
347 access and the use of the photo-documentation machine during the COVID-19 pandemic and

348 to the Graduate School of the Faculty of Veterinary Sciences (UACH) for co-financing the
349 acquisition of the plate reader (HR801, Shenzhen Highcreation Technology Co.,Ltd). We
350 also thank the SEREMI Coquimbo region, Servicio de Salud de Coquimbo, Hospital
351 Regional de Ovalle, and Municipality of Monte Patria for their logistical support, and Vinka
352 Valencia, Paula Rojas, Cristian Brevis and Paxelia Huertas for their invaluable assistance
353 during field work for the pre-pandemic sampling. Pre-pandemic sampling was supported by
354 EU-LAC Health (EULAC/FONIS T020067), through the PERITAS (Molecular
355 epidemiological studies on pathways of transmission and long-lasting capacity building to
356 prevent cystic echinococcosis infection) project (G.A. EULACH16/T02-0067;
357 <https://www.iss.it/en/web/iss-en/who-cc-peritas>).

358

359 REFERENCES

- 360 1. WHO. COVID-19 Weekly Epidemiological Update. In: WHO COVID-19 Weekly
361 Epidemiological Update, Edition 94 [Internet]. 2022 p. 10. Available:
362 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2022)
363 [19---1-june-2022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2022)
- 364 2. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et
365 al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*.
366 2020;26: 1033–1036. doi:10.1038/s41591-020-0913-5
- 367 3. Huynh A, Arnold DM, Smith JW, Moore JC, Zhang A, Chagla Z, et al. Characteristics
368 of anti-sars-cov-2 antibodies in recovered covid-19 subjects. *Viruses*. 2021;13.
369 doi:10.3390/v13040697
- 370 4. Okba NMA, Müller MA, Li W, Wang C, Geurtsvankessel CH, Corman VM, et al.
371 Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in
372 Coronavirus Disease Patients. *Emerg Infect Dis*. 2020;26. doi:10.3201/eid2607.200841

- 373 5. Padoan A, Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical
374 performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and
375 antibody kinetics. *Clinical Chemistry and Laboratory Medicine*. 2020.
376 doi:10.1515/cclm-2020-0443
- 377 6. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody Detection and
378 Dynamic Characteristics in Patients with Coronavirus Disease 2019. *Clin Infect Dis*.
379 2020;71. doi:10.1093/cid/ciaa461
- 380 7. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al.
381 Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in
382 COVID-19. *Allergy: European Journal of Allergy and Clinical Immunology*. 2020.
383 doi:10.1111/all.14364
- 384 8. Wang P. Significance of IgA antibody testing for early detection of SARS-CoV-2. *J*
385 *Med Virol*. 2020/12/17. 2021;93: 1888–1889. doi:10.1002/jmv.26703
- 386 9. Yu H-Q, Sun B-Q, Fang Z-F, Zhao J-C, Liu X-Y, Li Y-M, et al. Distinct features of
387 SARS-CoV-2-specific IgA response in COVID-19 patients. *The European respiratory*
388 *journal*. 2020. doi:10.1183/13993003.01526-2020
- 389 10. Infantino M, Manfredi M, Grossi V, Lari B, Fabbri S, Benucci M, et al. Closing the
390 serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-
391 2 IgA antibodies. *J Med Virol*. 2021;93: 1436–1442.
392 doi:<https://doi.org/10.1002/jmv.26422>
- 393 11. Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al.
394 Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody
395 detection in severe and mild COVID-19 cases using a Luminex bead-based assay. *J*
396 *Virol Methods*. 2021;288. doi:10.1016/j.jviromet.2020.114025
- 397 12. Nuccetelli M, Pieri M, Gisone F, Sarubbi S, Ciotti M, Andreoni M, et al. Evaluation of

- 398 a new simultaneous anti-SARS-CoV-2 IgA, IgM and IgG screening automated assay
399 based on native inactivated virus. *Int Immunopharmacol.* 2021;92.
400 doi:10.1016/j.intimp.2020.107330
- 401 13. Jääskeläinen AJ, Kekäläinen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti
402 O, et al. Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs
403 using coronavirus disease (COVID-19) patient samples. *Eurosurveillance.* 2020;25.
404 doi:10.2807/1560-7917.ES.2020.25.18.2000603
- 405 14. Ibrahim NK. Epidemiologic surveillance for controlling Covid-19 pandemic: types,
406 challenges and implications. *J Infect Public Health.* 2020;13: 1630–1638.
407 doi:<https://doi.org/10.1016/j.jiph.2020.07.019>
- 408 15. Goldstein ND, Wheeler DC, Gustafson P, Burstyn I. A Bayesian approach to
409 improving spatial estimates of prevalence of COVID-19 after accounting for
410 misclassification bias in surveillance data in Philadelphia, PA. *Spat Spatiotemporal
411 Epidemiol.* 2021;36: 100401. doi:10.1016/j.sste.2021.100401
- 412 16. Burstyn I, Goldstein ND, Gustafson P. Towards reduction in bias in epidemic curves
413 due to outcome misclassification through Bayesian analysis of time-series of
414 laboratory test results: case study of COVID-19 in Alberta, Canada and Philadelphia,
415 USA. *BMC Med Res Methodol.* 2020;20: 146. doi:10.1186/s12874-020-01037-4
- 416 17. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. Detection of
417 Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike
418 Protein in COVID-19 Patients. *medRxiv Prepr Serv Heal Sci.* 2020.
419 doi:10.1101/2020.04.20.20071423
- 420 18. Tok TT, Tatar G. Structures and Functions of Coronavirus Proteins: Molecular
421 Modeling of Viral Nucleoprotein. *Int J Virol Infect Dis.* 2017;2.
- 422 19. Lisboa-Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et

- 423 al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-
424 analysis. *BMJ*. 2020;370: m2516. doi:10.1136/bmj.m2516
- 425 20. Espejo AP, Akgun Y, Mana AF Al, Tjendra Y, Millan NC, Gomez-Fernandez C, et al.
426 Review of current advances in serologic testing for COVID-19. *American Journal of*
427 *Clinical Pathology*. 2020. doi:10.1093/AJCP/AQAA112
- 428 21. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel
429 coronavirus spike protein by a SARS coronavirus-specific human monoclonal
430 antibody. *Emerging Microbes and Infections*. 2020.
431 doi:10.1080/22221751.2020.1729069
- 432 22. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses:
433 Challenges and pitfalls. *Virus Res*. 2014;194. doi:10.1016/j.virusres.2014.03.018
- 434 23. Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C, et al. A high-
435 throughput cell- And virus-free assay shows reduced neutralization of SARS-CoV-2
436 variants by COVID-19 convalescent plasma. *Sci Transl Med*. 2021;13.
437 doi:10.1126/scitranslmed.abi8452
- 438 24. Infantino M, Damiani A, Gobbi FL, Grossi V, Lari B, Macchia D, et al. Serological
439 assays for sars-cov-2 infectious disease: Benefits, limitations and perspectives. *Isr Med*
440 *Assoc J*. 2020;22.
- 441 25. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD
442 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration.
443 *BMJ Open*. 2016;6. doi:10.1136/bmjopen-2016-012799
- 444 26. Olivares F, Muñoz D, Fica A, Delama I, Alvarez I, Navarrete M, et al. Covid-19 in
445 Chile. The experience of a Regional reference Center. Preliminary report. *medRxiv*.
446 2020; 2020.06.14.20130898. doi:10.1101/2020.06.14.20130898
- 447 27. Woo PCY, Lau SKP, Tsoi H, Chan K, Wong BHL, Che X, et al. Relative rates of non-

- 448 pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. *Lancet*
449 (London, England). 2004;363: 841–845. doi:10.1016/S0140-6736(04)15729-2
- 450 28. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG
451 responses in COVID-19. *Cellular and Molecular Immunology*. 2020.
452 doi:10.1038/s41423-020-0474-z
- 453 29. R_Core_Team. R: A Language and Environment for Statistical Computing. Vienna,
454 Austria: R Foundation for Statistical Computing; 2019.
- 455 30. Obuchowski NA. ROC analysis. *AJR Am J Roentgenol*. 2005;184: 364–372.
456 doi:10.2214/ajr.184.2.01840364
- 457 31. Pastore M. Overlapping: a R package for Estimating Overlapping in Empirical
458 Distributions. *J Open Source Softw*. 2018;32: 1023.
- 459 32. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
460 *Biometrics*. 1977;33: 159–174.
- 461 33. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the
462 early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med*. 2021;13.
463 doi:10.1126/scitranslmed.abd2223
- 464 34. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral
465 response to diagnose novel coronavirus disease (COVID-19). *Clin Infect Dis*. 2020;71.
466 doi:10.1093/cid/ciaa310
- 467 35. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to
468 SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020;26. doi:10.1038/s41591-
469 020-0897-1
- 470
- 471

472 **FIGURE CAPTIONS**

473 Figure 1: Combined immunodetection of SARS-CoV-2-specific IgA/IgM/IgG
474 immunoglobulins in response against the Nucleocapsid (Np) and Region Binding Domine of
475 Spike Protein (RBD). Oil painting picture schematic of SARS-CoV-2 viral structure (top
476 panel), N-protein (Np) and RBD from S-protein are showed in red and light orange,
477 respectively. Absorbance at 450 nm plotted for combined detection of IgA, IgM, and IgG
478 specific immunoglobulin isotypes for Np and RBD ELISAs (lower left and lower right panel,
479 respectively). Forty-four sera from pre-pandemic individuals and fifty sera from COVID-19
480 patients were tested. To compare both groups, a Mann-Whitney U-test was used. Mean+/-SD
481 and P values are showed ($P < 0.0001$).

482

483 Figure 2: Receiver Operating Characteristic (ROC) curves for the combined detection of
484 SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes using RBD or Np antigens.
485 Graph of ROC curve and two graph curves (sensitivity and specificity for different cut-off)
486 for Np-specific immunoglobulins (Panel A: top and bottom, respectively), and RBD-specific
487 immunoglobulins (Panel B: top and bottom, respectively), are shown. Forty-four sera from
488 pre-pandemic individuals and fifty sera from COVID-19 patients were tested. AUC, area
489 under the curve of ROC.

490

491 Figure 3: Estimated sensitivity and specificity distribution curves for the selected OD cut off
492 ($Np = 0.88$ & $RBD = 0.996$). The overlapping area between the sensitivity curves of Np
493 ELISA vs. RBD ELISA (Panel A), and the overlapping area between the specificity curves of
494 Np ELISA vs. RBD ELISA (Panel B).

495

496 Table 1. Cross-tabulation of in-house ELISAs (Np & RBD ELISA) results and a commercial
497 lateral flow chromatographic immunoassay (LFCI) result

		LFCI*	
		Positive	Negative
Np ELISA	Positive	44	2
	Negative	3	45

		Positive	Negative
RBD ELISA	Positive	44	7
	Negative	3	40

498 *The Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow), LIVZON, China

499

500

501 Table 2. Cross-tabulation of SARS-CoV-2 infection status and a commercial lateral flow
502 chromatographic immunoassay (LFCI) test result

		Disease Status	
		Confirmed	Control
LFCI*	Positive	47	0
	Negative	3	44

503 *The Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow), LIVZON, China

504

505









Figure 1

A**B**

Two Graph ROC curve: Np



Two Graph ROC curve: RBD




Figure 2





Figure 3